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Abstract
Obstructive sleep apnea (OSA) has a high prevalence in patients with obesity. Only patients with clinical symptoms of OSA are
admitted to polysomnography; however, many patients with OSA are asymptomatic. We aimed to create and validate a population-
based risk score that predicts the severity of OSA in patients with obesity.
We here report the cross-sectional analysis at baseline of an ongoing study investigating the long-term effect of bariatric surgery on
OSA. One-hundred sixty-one patients of the Obesity Center of the Catholic University Hospital in Rome, Italy were included in the
study. The patients underwent overnight cardiorespiratory monitoring, blood chemistry analyses, hepatic ultrasound, and
anthropometric measurements. The patients were divided into 2 groups according OSA severity assessed by the apnea-hypopnea
index (AHI): AHI< 15= no or mild and AHI ≥ 15moderate to severe OSA. A statistical prediction model was created and validated. C
statistics was used to evaluate the discrimination performance of the model.
The prevalence of OSAwas 96.3%with 74.5% of the subjects havingmoderate/severe OSA. Sex, bodymass index, diabetes, and
age were included in the final prediction model that had excellent discrimination ability (C statistics equals to 83%). An OSA risk chart
score for clinical use was created.
Patients with severe obesity are at a very high risk for moderate or severe OSA in particular if they are men, older, more obese, and/
or with type 2 diabetes. The OSA risk chart can be useful for general practitioners and patients as well as for bariatric surgeons to
select patients with high risk of moderate to severe OSA for further polysomnography.
Abbreviations: AHI = apnea-hypopnea index, ALT = alanine transaminase, AST = aspartate transaminase, BMI = body mass
index, OGTT = oral glucose tolerance test, OSA = obstructive sleep apnea, PM = portable sleep monitoring, ROC = receiver
operating characteristic curve, T2D = type 2 diabetes.
Keywords: obesity, prediction risk chart, sleep apnea
1. Introduction
In the general population, obstructive sleep apnea has a
prevalence of approximately 10–17% in men and 3–9% in
women.[1] Obesity represents the major risk factor for OSA
development with 58% of moderate to severe OSA being
associated with obesity.[2–4]
Patients with OSA are at high risk of all-cause mortality,[5,6]
particularly cardiovascular related,[7] and have a 6 times higher
risk of being involved in a traffic accident.[8] In addition, OSA is
linked to nonalcoholic fatty liver disease[9] and the intermittent
hypoxia during sleep that arises during OSA may lead to
oxidative stress, lipid peroxidation, and progress of the
disease.[10] Furthermore, OSA affects the quality of life[11] which,
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at least partly, can be improved by treatment.[12] OSA is also
important in a perioperative setting as it is a risk factor of
postoperative complications[13] and the identification and
treatment of OSA is recommended before bariatric surgery.[14]
Hence, identifying patients withOSA in the general population as
well as in a perioperative setting is essential. However, more than
80% of the patients with OSA remain undiagnosed.[15]
Screening questionnaires might help to identify patients with
OSA. Nevertheless, the sensitivity, specificity, and predictive
value of self- or interview-administered questionnaires depend
from many variables including the specific reference population,
the OSA prevalence in the study sample and the disease
severity.[16,17] Even more importantly, the patients often
underreport their symptoms or are asymptomatic which makes
it harder to detect the disease.[18]
Standard laboratory polysomnography is considered the
golden standard for the diagnosis of OSA, although portable
sleep monitoring systems at home (PM) are gaining more and
more interest in relation to their cost-effectiveness. The cost for
PM has been calculated to be 256.5±16.9 EUR or 348.2±22.9
USD which can be compared with the laboratory polysomnog-
raphy cost of 548.1±45.7 EUR or 744.1±62.0 USD.[19] A recent
study evaluated in the general population the effectiveness to
assess OSA with home sleep testing without a sleep medicine
specialist. The results were promising where the diagnosis was
missed in <6% of the patients and 16.8% of the patients were
misclassified.[20] However, there is still a need to identify those
patients who need to undergo polysomnography.
Here we aim to report the prevalence of OSA in a high risk
population of patients evaluated for bariatric surgery, to
highlight those factors associated with its severity and to create




This clinical study (ClinicalTrial.gov ID NCT03223467) has
been approved by the ethic committee of the Catholic University
of the SacredHeart in Rome, Italy. All participants gave informed
consent to participate in the study.
2.2. Study design
We here report the cross-sectional analysis at baseline of an
ongoing study investigating the long-term effect of bariatric
surgery on OSA. The objective for the present study was to
investigate the prevalence and severity of OSA in patients
evaluated for bariatric surgery, to study the possible links
between components in the metabolic syndrome and the severity
of OSA and to create and validate a model that predicts moderate
to severe OSA.
One-hundred sixty-one patients screened for bariatric surgery
were enrolled between January 1, 2012 and December 31, 2012
andbetween January 1, 2017 andDecember 31, 2017. Initially, 86
patients were recruited in 2012 and 85 patients were recruited
during 2017. Nine patients (4 patients during 2012 and 5 patients
during 2017) were excluded from the study because they were not
able to perform polysomnography. The patients were recruited
during their hospitalized evaluation for bariatric surgery at the
ObesityCenter atCatholic UniversityHospital inRome, Italy. The
patients underwent usual evaluation for possible bariatric surgery
with fasting blood samples, anthropometric measurements, and
ultrasound of the abdomen to evaluate hepatic steatosis. An
overnight cardiorespiratory monitoring with VitalNight 8 (Vital-
Aire, Milan, Italy) was also performed to investigate the presence
and severity ofOSA.All blood sampleswere analyzed at the central
laboratory of the Catholic University Hospital.
The participants underwent a 3-hour oral glucose tolerance
test (OGTT). Patients who had a plasma glucose value above 200
mg/dL after 2-hour OGTT or already had a known diagnosis of
type 2 diabetes (T2D) were categorized as patients with T2D.
Presence of antihypertensive medications was considered as a
diagnosis of hypertension.
2.3. Statistical analysis
Patientswere classified into 2 groups according to theOSA severity
on the basis of their apnea-hypopnea index (AHI): AHI< 15 was
classified as no or mild OSA, whereas AHI ≥ 15 was classified as
moderate or severe OSA. Student t test was used to evaluate
possible differences between the 2 groups for continuous variables
and Fisher exact test was used to study possible association
between study groups and categorical variables. All statistical
analyses were performed with IBM SPSS Statistics for Windows
(version 21.0; IBM Corp, Armonk, NY) or the R package.
2.3.1. OSA prediction model. The AHI score was considered as
a binary variable with class 0 for no or mild OSA (AHI <15) and
class 1 for moderate to severe OSA (AHI values ≥15). Nine
variables for the prediction of the binary AHI outcome were
evaluated on the study population of 161 patients with the aim of
finding the best set of predictors. The variables initially included
in the model were: age, sex, T2D (0 = absence, 1 = presence),
fasting glucose, body mass index (BMI), hypertension medication
(0 = no administered drug, 1 = administered drug), aspartate
transaminase (AST), alanine transaminase (ALT), and hepatic
steatosis. The validity of the full model (the model including all
the nine measured predictors) was assessed by a model validation
approach (see Section 2.3.2 for more details). On the basis of the
obtained results, a reduced model was then tested and validated.
2.3.2. Model validation. To establish the best model for
predicting the probability of moderate or severe OSA occurrence,
the following procedure was set up.
The data set was split into a fitting population and a validation
population by using the internal/validation/data-splitting meth-
od. The internal/validation/data-splitting method was chosen to
limit the possible increase in bias that can occur with other
techniques for internal validation such as Bootstrapping
technique if the original study population contains biases. A
random portion of the population (70%, n = 113) was used as
fitting population for model development. The number of
subjects in the fitting population was based on the rule-of-thumb
that N=104 + m (m= the number of predictors) when testing for
partial correlations.[21] The model was then tested, in terms of its
performance on the remaining validation population (30%, n=
48). Computation of the C statistic was used to indicate the
discrimination performance of the model. The C statistic
represents a measure of the model’s performance in terms of
the model discrimination ability to separate subjects with
different outcomes, and for the logistic model, it is equivalent
to the area under the curve of the receiver operating characteristic
(ROC) curve associated to the model.[22] Values of C between 0.8
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and 0.9 were considered to give an excellent discrimination. An
OSA risk chart was constructed based the probability of
moderate to severe OSA.
The steps of the procedure are summarized as follows:
1. Data splitting: The studied population was split into a fitting
population and a validation population.
2. Model fitting: The model was fitted onto data from the fitting
population and the model coefficients for the variables
included into the model, along with their standard errors
and significance levels, were computed.
3. The prediction model was applied to the validation population.
4. Computation of the probabilities: For each subject, both from
the fitting population and the validation population, the
probability of the studied outcome was computed on the basis
of the patient’s covariate values. Each subject was therefore
characterized by the values of the covariate set, the outcome
(AHI 0/1) and by the estimated probability of the outcome.
5. Computation of the C statistics: For both the fitting and the
validation populations, the C statistics was computed. The
accuracy (percentage of true positive and negative on the total
subjects) of the prediction model was also computed.
6. Procedure repetition: The entire procedure (data splitting,
modelfitting, probability computation)was repeated200 times.
7. Model fitting onto the whole population: The model was then
fitted using all the original data.
8. Results analysis: At the end of the procedure, the distribution
of different indicators was computed: for each variables,
frequency histograms of the estimated coefficients along with
their associated standard errors and levels of significance were
plotted. The importance index of each variable computed from
each data splitting and model fitting was also plotted.
The estimated coefficients from the whole population were
compared with the respective distributions (they should be
centered around the estimates obtained on the whole sample); the
distribution of the variability of themodel coefficients indicates to
which extent the results are dependent from the subpopulation
used; comparison between the distribution of the C statistic
computed on the fitting and the validation sample, along with the
distribution of their Delta provide indication of the discrimina-
tion power of the model. It is expected that the C statistic is larger
for the fitting sample than for the validation sample. A model
with a high discrimination power presents small drops in the
values of the C statistic when computed on the validation sample
with respect to values computed on the fitting sample for which
the values are expected to be larger (C Delta distribution centered
around the zero).
On the basis of the obtained results on the full model, the entire
procedure is repeated on the subset of the most important
variables to test and validate the final reduced model including
the most meaningful predictors. Once the model validation is
assessed the fitted coefficients used to compute the probability of
the outcome on a generic patient will be those obtained from the
“reduced model” fitting on the whole population sample.
3. Results
3.1. Patient characteristics
Patient characteristics are reported in Table 1. The proportions of
men and women were balanced in the whole study population
(49.7% vs 50.3%). A very high prevalence of OSA, equal to
96.2%of the patients, was observed. Themajority, about 74.5%,
of the patients suffered fromOSA that was considered to be either
moderate (21.7%) or severe (52.8%), whereas 21.7% had mild
OSA.
The proportions of men and women in the 2 AHI groups were
different. Only 19.5% of the patients with no or mild OSA were
men compared to 60% of the patients with moderate or severe
OSA. BMI was higher in patients with moderate/severe OSA than
in patients with no/mild OSA (47.14±8.16 vs 44.01±6.85kg/
m2, P< .05). More patients with moderate/severe OSA had
hypertension (62.5% vs 31.7%, P< .01) and T2D (44.7% vs
18.4%, P< .01) than those with no/mild OSA. Hepatic steatosis
assessed by ultrasonography was similar in the 2 categories.
3.2. Selection of variables and validation of a prediction
model of OSA
Four of the 9 variables included in the full model were entered the
final reduced model. All the selected variables from the full
model, age, sex, BMI, and diabetes status, displayed a median
importance coefficient >50%, a median P-value <.15, and the
Table 1
Baseline characteristics of study participants.
All
n=161
No or mild OSA
n=41
Moderate or severe OSA
n=120
Age, yrs 46.48±9.68 42.83±11.28 47.73±8.78
∗
Men, n (%) 80 (49.7%) 8 (19.5%) 72 (60%)
∗∗
Weight, kg 133.90±26.00 121.59±22.77 138.26±25.77
∗∗
Height, cm 169.76±9.99 165.95±6.52 171.11±10.66
∗
BMI, kg/m2 46.33±7.94 44.01±6.85 47.14±8.16
∗∗∗
Fasting glucose, mg/dL 115.27±53.86 110.59±73.91 116.82±45.65
AST, IU/L 23.81±13.66 21.33±13.63 24.74±13.62
ALT, IU/L 31.25±19.98 27.16±25.71 32.56±17.70
Systolic blood pressure, mm Hg 130.46±16.88 121.59±14.83 134.07±16.43
∗
Diastolic blood pressure, mm Hg 79.04±10.67 73.64±8.19 81.24±10.84
∗
Hypertension, n (%) 88 (54.7) 13 (31.7) 75 (62.5)
∗
Hepatic steatosis, n (%) 135 (91.2 32 (84.2) 103 (93.6)
Type 2 diabetes, n (%) 58 (38.2) 7 (18.4) 51 (44.7)
∗
ALT= alanine transaminase, AST= aspartate transaminase, BMI=body mass index, OSA= obstructive sleep apnea.
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average of the coefficient distributions were centered around the
estimated coefficient obtained by fitting the model on the whole
study population. Estimated coefficients from the whole sample,
the average of the coefficient distributions and the median of the
P-values and importance index of the respective distributions
from the full model are displayed in Table 2.
Coefficient estimates of the variables in the final reduced model
in the training sample were similar to the estimated coefficients
when the model was fitted onto the whole population (Table 3).
Distributions of the coefficient estimates for age, sex, T2D status,
and BMI in the training sample are shown in Figure 1A, where the
average and median values of the distributions are indicated
together with the obtained values from the model fitting over the
whole study population.
3.3. Discrimination power of the model
C statistics were computed to indicate the discrimination power
of the model (Fig. 1B). As expected, the average of C statistics was
a little higher in the fitting sample than in the validation samples
(83±3% and 80±8%, respectively) with the absolute delta of
3.6±11% and the distribution of the accuracy of 80±5% for the
reduced model. When the reduced model was applied on the
whole study population, C statistics was 83%, indicating an
excellent discrimination of the reduced model in separating
subjects with and without moderate/severe OSA.
An ROC curve was constructed and an optimal cut-off value
of 0.735 for the model was calculated (Fig. 2). At this value, the
final reduced model displayed a sensitivity of 78.8% and a
specificity of 81.6% to identify patients with moderate or
severe OSA.
3.4. OSA risk score for clinical use
The final reduced model was used to create an OSA risk chart
score. The cut-off values obtained from the ROC curve was used
to identify patients at risk. Patients presenting probability of
developing moderate/severe OSA<0.5 were classified at very low
risk (green), estimated probabilities between 0.5 and 0.735 were
associated to moderate risk (yellow), values between 0.735 and
0.85 were associated to high risk (orange) and patients presenting
probabilities >0.85 were classified at very high risk. The chart is
reported in Figure 3. In the OSA risk chart score, 4 different
charts are used depending on the categorical variables in the
model (sex and T2D status) and color code indicate risk of
moderate/severe OSA.
4. Discussion
In this cross-sectional study in patients evaluated for bariatric
procedures, the prevalence of OSA was very high. Several
variables were associated with OSA severity but the best
predictors of moderate to severe OSA were age, sex, BMI, and
diabetes status, where men, older, higher BMI, and with T2D
being at progressively higher risk for OSA of moderate or severe
degree. Based on our prediction model, we also constructed an
OSA risk chart that can be helpful for clinicians to select patients
for admission to polysomnography.
In our study, we 1st evaluated how known risk factors for OSA
could predict the severity of the disease and selected the best
predictors for our final model. To obtain a model that could fit a
general population with obesity a validation approach was
implemented in the statistical analyses. The statistical methods
used in this study give the possibility to evaluate if the model is
Table 3
Descriptive statistics from the fitting distributions for the “reduced model” along with the estimated coefficients from the whole sample.
Results from the whole sample Results from the training samples
Variable Estimated coefficient Standard error P-value Average coefficient P-value
∗
Age 0.09 0.03 .001 0.09 .006
Gender (if male) 1.97 0.49 5.7E05 2.04 <.001
Type 2 diabetes (if yes) 1.58 0.85 .06 2.89 .15





Descriptive statistics from the fitting distributions for the “full model” along with the estimated coefficients from the whole sample.




Age 0.079418 0.084087 .03 81.33985
Gender (if male) 1.643158 1.740187 .03 85.79708
Fasting glucose 0.00584 0.00543 .26 35.12048
AST 0.001808 0.006 .66 4.66588
ALT 0.0094 0.000217 .50 14.73533
Type 2 diabetes (if yes) 1.752343 3.281357 .13 52.59695
Steatosis (if yes) 0.830227 0.907455 .38 25.34227
Hypertension Medication (if yes) 0.870754 0.960449 .18 46.54629
BMI 0.114494 0.127891 .02 100
ALT= alanine transaminase, AST= aspartate transaminase, BMI=body mass index, SD= standard deviation.
∗
Represent the median values of the P-values and importance index from the 200 procedure repetitions.
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able to describe the dependence of the outcome on the selected
predictors both in the analyzed sample and in the entire reference
population. By performing a data-splitting method respecting the
minimal numbers of subjects for multiple regression analysis and
maintaining the proportions of subjects in each AHI group, we
have tried to limit possible sources of bias that could have
occurred using other techniques for internal validation.
Our prediction model displayed that increasing age and BMI
together with presence of T2D and male sex were identified as
risk factors for moderate or severe OSA in our study. These
results are in line with previous reported risk factors for OSA[23]
and further strengthen previous studies where links between OSA
and altered glucose homeostasis have been reported.[24–29]
Based on our prediction model, we have created an OSA risk
chart that can be useful for general practitioners as well as for
bariatric surgeons when selecting patients for admission to
polysomnography. The C statistic showed an excelled discrimina-
tion (83%) between patients with low to high risk and a cut-off of
0.735 provided a sensitivity of 78.8% and a specificity of 81.5%.
According to the American Society for Metabolic and Bariatric
Surgery, ASMBS, the recent clinical practice only admits patients
with clinical symptoms of OSA to polysomnography[30] and many
of thequestionnaires used for screeningofOSAfocusonsymptoms.
However,manypatientswithOSAare asymptomatic.[18]OurOSA
risk chart is based on anthropometry and blood chemistry and can
be used as an important complement to the questionnaires to select
patients for admission to polysomnography.
About 96% of our study population had OSA and about 75%
were considered to have OSA of moderate or severe degree. The
prevalence of OSA in the bariatric surgery population has been
previously reported in the range 71% to 91% which means that
our prevalence is in the upper level[18,31–33] probably depending
on differences in study population composition. Our high
prevalence number of OSA highlights the importance of
screening for OSA. In addition, patient eligible for bariatric
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Figure 2. Receiver operating characteristic curve reporting the sensitivity and
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Figure 1. (A) Distributions of the coefficient estimates along with the average value (blue vertical line), median value (vertical black line), and the coefficient estimates
on the whole sample (vertical red line) in the “reduced model.” (B) Distribution of the C statistics computed over the fitting samples and over the validation samples
along with the distribution of the absolute deltas and of the accuracy. Blue lines and black lines represent the average and the median values of the distributions
respectively whereas the red lines represent the obtained values from the model fitting over the whole sample.
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where evaluation of OSA is common, could be at high risk of not
having a diagnosis and thus they would not receive a correct
treatment and the treatment benefits. However, selecting the right
patients for polysomnography is important due to limited health
care budget. In our study population, 25% of the subjects had no
OSA ormildOSA. Screening with our OSA risk chart would have
resulted in savings ranging from 7225.15 USD (83% of 25=
20.75USD 348.2) to USD 15400.1 (83% of 25=20.75USD
744.1) for portable sleep monitoring systems use at home or
polysomnography test at the hospital, respectively.
In conclusion, our study shows that morbidly obese subjects
are at a very high risk for moderate to severe OSA in particular if
they are men, older, have higher BMI and with T2D. All
predictors of the severity of OSA in our study are well-known risk
factors for OSA but to help clinicians to identify patients with
high risk of moderate and severe OSA, we created an OSA risk
chart score that can predict the presence of OSA of moderate to
severe intensity with 83% accuracy. Our OSA risk chart is not
dependent on the symptoms of OSA which many other OSA
screening tools are, such as the STOP-Bang questionnaire and
Berlin questionnaire.[34] Hence, our OSA risk chart can be
especially useful to identify patients that do not report symptoms
even though they still have the disease.[18] However, external
validation in a different population is needed to further evaluate
our OSA risk chart.We hope that our OSA risk chart in the future
can be useful for general practitioners and patients as well as for
bariatric surgeons and can permit to address to polysomnog-
raphy only those patients with moderate or severe OSA with a
particular focus to those patients who do not report symptoms of
OSA but still have the disease.
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